Hypermethylation of the distal CEBPA promoter region has been reported to result in the downregulation of CEBPA expression in several malignancies. However, the clinical implication of CEBPA hypermethylation in acute myeloid leukemia (AML) remains unclear. , n ¼ 165) were defined by using two-way hierarchical clustering. With a median follow-up of 48 months, among the 125 patients receiving standard induction therapy, CEBPA high-meth was associated with better treatment response (complete remission rate 93.3% versus 73.6%, P ¼ 0.116). In patients with normal karyotype and without CEBPA and NPM1 mutations, the CEBPA high-meth had longer overall survival (OS) than the CEBPA low-meth (P ¼ 0.028). Multivariate analysis further supported that the CEBPA methylation was an independent prognostic factor for disease free-survival (hazard ratio ¼ 0.416; 95% confidence interval, 0.223-0.777, P ¼ 0.006) and OS (hazard ratio ¼ 0.406; 95% confidence interval, 0.166-0.996, P ¼ 0.050). We conclude that CEBPA methylation status is a useful prognostic biomarker for AML patients.
Introduction
Acute myeloid leukemia (AML) is a clonal disorder characterized by acquired genetic abnormalities in hematopoietic progenitors, including an early block of granulopoiesis, and excessive proliferation of blasts.
1,2 CCAAT/enhancer-binding protein a (C/EBPa), encoded by CEBPA gene, is a basic leucine zipper transcription factor partaking in the transcriptional regulation of key genes involved in hematopoiesis and inhibits cell proliferation during granulocyte differentiation. 3, 4 Loss of C/EBPa expression or function resulting from epigenetic modification of CEBPA gene or CEBPA mutations has been observed in several human malignancies. [5] [6] [7] [8] [9] According to previous publications, CEBPA mutations correlate with better event-free, disease-free and overall survival (OS) in AML patients, [10] [11] [12] [13] especially in patients with double CEBPA
mutations (CEBPA double-mut
). [14] [15] [16] Results from in vivo experiment have further verified the critical role for C/EBPa in myeloid leukemogenesis. 17 In addition, suppression of CEBPA expression by fusion proteins generated from translocation t(8;21), 18 t(3;21), 19 inv(16) 20 or t(9;22), 21 as well as blocking of C/EBPa function by FLT3-activating mutations, 22 arrested the differentiation of myeloid progenitors. Results from these studies pointed to the critical importance of C/EBPa during granulocyte differentiation and CEBPA as a tumor suppressor gene.
Recent reports have shown that epigenetic modification of the distal CEBPA promoter region (À1422 to À896 upstream from transcription start site) resulted in the downregulation of CEBPA expression in lung cancer, 5 head and neck squamous cell carcinoma 6 and pancreatic cancer cells. 23 Apart from solid tumors, several observations of epigenetic modification of CEBPA in AML have been reported. Chim et al. 24 found aberrant methylation in the CEBPA core promoter (À141 to À15 from transcription start site) in a small proportion (2.85%) of patients with AML. Wouters et al. 25 have identified a subgroup of AML patients (1.4%) in which the CEBPA gene was silenced in association with CEBPA core promoter methylation. Hackanson et al. 7 have observed methylation in the distal CEBPA promoter region in 51% of selected AML patients. Owing to the differences in the selected patient populations and the CEBPA promoter region utilized for analysis in these studies, the clinical implications of CEBPA methylation in AML remains unclear. In this study, we evaluated the CEBPA methylation status and its clinical implications in 193 unselected patients with de novo AML. We found that CEBPA hypermethylation appeared to be a favorable prognostic marker, in addition to the favorable karyotypes, nucleophosmin (NPM1) mutation and CEBPA mutation, in patients with de novo AML.
Materials and methods

Bone marrow cells from AML patients and cell lines
Bone marrow (BM) samples from 193 unselected, newly diagnosed patients with de novo AML were collected and cryopreserved in the Department of Internal Medicine, National Taiwan University Hospital (Taipei, Taiwan) from 2001 to 2006. This study was approved by the Institutional Review Board of the hospital (serial no. 200612031R), and written informed consent was obtained from all patients. Of a total of 193 patients, 125 non-acute promyelocytic leukemia (non-APL) patients underwent conventional induction chemotherapy with an anthracycline (doxorubicin or idarubicin) for 3 days and cytosine arabinoside for 7 days; 16 APL patients received combined alltrans retinoic acid and chemotherapy. The remaining 52 patients were only treated with low-dose chemotherapy and/or supportive care and were excluded from survival analyses. After complete remission (CR) was achieved, patients received consolidation therapy with 2-4 courses of high dose of cytosine arabinoside, with and without an anthracycline. Fourteen patients received hematopoietic stem cell transplantation.
U937, HL60 and K562 cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum.
RNA isolation, reverse transcription and quantitative real-time PCR
Total RNAs were isolated from various cell lines and BM cells using RNAzol B Reagent (Tel-Test, Friendswood, TX, USA) and reverse transcribed to cDNA using Moloney murine leukemia virus reverse transcriptase (Epicentre, Robbinsville, NJ, USA) coupled with oligo-dTs and random hexamers under standard conditions. Reverse transcription and quantitative real-time PCR (Q-RT-PCR) was carried out on ABI Prism 7000 (Applied Biosystems, Foster City, CA, USA) using SYBR green as the detection dye. PCR conditions consisted of one cycle of 50 1C for 2 min and 95 1C for 10 min, followed by up to 40 cycles of 95 1C for 15 s (denaturation) and 60 1C for 1 min (annealing/ extension). The specificity was confirmed via dissociation curve following the reaction. The primer pairs were as follows:
The transcript levels of CEBPA were normalized to those of HPRT, and were calculated using the DC T method as follows:
Bisulfite treatment
Bisulfite treatment of genomic DNA was performed using the Epitect Bisulfite Kit according to the manufacturer's instructions (Zymo, Orange, CA, USA). Bisulfite-treated DNA was used in subsequent DNA methylation analyses.
Bisulfite sequencing and methylation-specific PCR analysis of gene methylation
Primers used for bisulfite sequencing and methylation-specific PCR were identical to those published previously. 5, 24 Primer sequences and PCR conditions are shown in Supplementary  Table 1 (Table S1 ). The PCR products for bisulfite sequencing were gel purified using a gel extraction kit (Genemark Technology, Taipei Taiwan), and the methylation patterns were determined using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on an automated ABI 3730 Genetic Analyzer (Applied Biosystems). CpGenome universal methylated DNA (Chemicon, Temecula, CA, USA) followed by bisulfite treatment was used as a methylation-positive control.
Quantitative MassARRAY analysis of gene methylation
Quantitative MassARRAY analysis of CEBPA promoter methylation was performed according to the manufacturer's instructions (Sequenom, San Diego, CA, USA). The analyzed region and CpG sites of CEBPA promoter were shown in Supplementary Figure S1 and the primers used were according to SEQUENOM Standard EpiPanel (Sequenom, November 2007 version, and Supplementary Table S1 ). The PCR mixture contained 10 ng bisulfite-treated DNA, 200 mM dNTP, 0.2 U of Hot Start Taq DNA polymerase (Qiagen, Valencia, CA, USA), and 0.2 mM forward and reverse primers in a total volume of 5 ml. The PCR mixture was preheated for 15 min at 94 1C and then incubated in 45 cycles of 94 1C for 20 s, 62 1C for 30 s and 72 1C for 1 min, followed by 72 1C for 3 min. Redundant dNTPs were digested by adding 1.7 ml H 2 O and 0.3 U of shrimp alkaline phosphatase (Sequenom). The reaction was performed at 37 1C for 20 min, and heat inactivated at 85 1C for 5 min. The in vitro transcription mixture was prepared using a MassCLEAVE kit (Sequenom), including 0.22 ml T cleavage mix, 3.14 mM dithiothreitol, 20 U of T7 RNA and DNA polymerase, 0.09 mg/ml RNase A, 1 Â T7 polymerase buffer and 2 ml of product of the PCR/shrimp alkaline phosphatase reaction in a total volume of 7 ml. The in vitro transcription and RNase A digestion were simultaneously reacted at 37 1C for 3 h. The mixture was further diluted with H 2 O to 27 ml, purified with CLEAN resin (Sequenom) and robotically dispensed onto silicon chips preloaded with matrix (SpectroCHIP; Sequenom). The spectra and the methylation values of matrix-associated laser desorption/ionization time-offlight mass spectrometry (Sequenom) were collected and analyzed with the Epityper analyzer software (Sequenom). The methylation level was calculated as the average values of three CpG units (units 2, 3 and 4; Supplementary Figure S1 ), which were automatically read out from this software.
Cytogenetic study
Chromosome analysis was performed as described previously. 26 BM cells from AML patients were harvested directly, or after 1-3 days of non-stimulated culture. Metaphase chromosomes were analyzed by the conventional trypsin-Giemsa banding technique and were karyotyped according to the International System of Human Cytogenetic Nomenclature. 27 
Mutational analysis and immunophenotyping
Mutation analyses in the CEBPA gene, AML1 gene (exons 3-8), KIT (exons 10-12), PTPN11 (exons 3 and 13), WT1 (exons 7 and 9), N-RAS (codons 12 and 13) and K-RAS (codons 12 and 13) were performed by PCR and direct sequencing on genomic DNA as described previously. 9, [28] [29] [30] In addition, mutations of NPM1 (4-bp insertion), FLT3/ITD, FLT3/TKD, JAK2V617F and MLL/PTD were determined by PCR followed by agarose gel electrophoresis or GeneScan analysis. 30, 31 To characterize the expression of surface markers in leukemic blasts, several monoclonal antibodies (BD Biosciences, San Jose, CA, USA) were used for flow cytometric analysis: 9 myeloid-associated antigens, including CD13, CD14, CD15 and CD33; lymphoid-associated antigens, consisting of CD2, CD7, CD10 and CD19; and lineage nonspecific antigens human leukocyte antigen-DR (HLA-DR), CD34 and CD56.
Statistical analysis
The correlation between CEBPA methylation and CEBPA expression in AML patients was analyzed with Spearman's rank correlation. Two-way hierarchical clustering based on the methylation values of units 2, 3 and 4 was presented in double dendrogram by using the Gene Expression Statistical System software (NCSS, Kaysville, UT, USA). A w 2 test was used to calculate the significance of association between CEBPA methylation and other discrete variables, such as age, sex, French-American-British subtypes, cytogenetics, gene mutations and cell surface markers; but if the expected values of contingency tables were smaller than 5, Fisher's exact test was used. Survival analysis of AML patients with high or low CEBPA methylation was estimated by Kaplan-Meier curves and log-rank test. Multivariate Cox's proportional hazard regression analysis was used to investigate independent prognostic factors for OS and disease-free survival. The proportional hazards assumption (constant hazards assumption) was examined by using time-dependent covariate cox regression before conduction multivariate Cox's proportional hazard regression. The variables included age, karyotype, CEBPA, NPM1 and FLT3-ITD. Patients who underwent hematopoietic stem cell transplantation were included, but censored at the transplant date. The receiver operating characteristic curve was constructed based on the CEBPA methylation levels calculated as stated above, and the area under the receiver operating characteristic curve was calculated to differentiate the CEBPA high-meth from the CEBPA low-meth . All statistical analyses were performed with the SPSS 13 software (SPSS Inc., Chicago, IL, USA), Statsdirect (England) and MedCalc software (http://www.medcalc.be/).
Results
Methylation of the CEBPA distal promoter inversely correlated with CEBPA expression in myeloid leukemia cells
We investigated the effect of CEBPA methylation on CEBPA expression in myeloid leukemic cells. The steady-state CEBPA mRNA levels of U937, HL60 and K562 cells were examined by Q-RT-PCR. The methylation patterns were semiquantified using bisulfite sequencing and methylation-specific PCR, and then quantified with MassARRAY method. The relative ratio of CEBPA mRNA over that of internal control (HPRT) in U937, HL60 and K562 cells was 0.732, 6.736 and 0.002, respectively ( Figure 1a) . Using bisulfite sequencing, hypermethylation was identified in the CEBPA distal and proximal promoter regions in U937 cells (À1423 to À1121) and K562 cells (À1423 to À725), but not in HL60 cells (Figure 1b) . Methylation-specific PCR analyses indicated a lack of methylation in the core promoter (À141 to À15) and exon 1 (À25 to þ 103) regions of CEBPA gene in all three cell lines (Supplementary Figure S2) . Subsequent quantitative MassARRAY analysis confirmed that the relative CpG methylation levels in the CEBPA distal promoter region (À1425 to À1260) were 0.988, 0.093 and 0.979 in U937, HL60 and K562 cells (Figure 1c ), respectively. These results suggested an inverse correlation between the methylation status in the CEBPA distal promoter region and its mRNA level.
Aberrant DNA methylation of the CEBPA distal promoter in patients with AML Next, we evaluated the CEBPA methylation status in a total of 193 patients with de novo AML using bisulfite sequencing and methylation-specific PCR methods. A substantial proportion of patients had heterogeneous methylation in the distal region (À1423 to À1121), but not in the proximal region (À1121 to À896) or in the core region (À141 to þ 103), of the CEBPA promoter. One 61-year-old female patient with M1 subtype of AML (no. 54) harbored hypermethylation throughout the distal and core CEBPA promoter and even the first exon. Notably, this patient had normal karyotype and without CEBPA, NPM1 or FLT3 mutations. The other patients harbored hypermethylation only in the distal CEBPA promoter region. We then correlated the methylation levels in the distal CEBPA promoter region with its transcript levels in leukemic cells prepared from 12 AML patients using quantitative MassARRAY and Q-RT-PCR, and observed a negative correlation (correlation coefficient ¼ À0.722, P ¼ 0.017; Figure 2a ). We concluded that the DNA methylation in the distal CEBPA promoter region correlated with the downregulation of CEBPA expression in patients with AML.
Correlation of CEBPA methylation with biological and clinical features
Among the cohort of 193 patients studied, the methylation levels ranged from 0.073 to 0.971, with a median value of 0.229. We divided the 193 patients into high CEBPA methylation group (CEBPA high-meth , n ¼ 28) and low methylation group (CEBPA low-meth , n ¼ 165) by using two-way hierarchical clustering based on the methylation values of units 2, 3 and 4 ( Figure 2b ). Clinical and laboratory features of these two groups are summarized in Table 1 . CEBPA high-meth tended to be younger (median 40.5 versus 53 years, P ¼ 0.026) than CEBPA low-meth . M3 subtype of AML had a significantly higher proportion of patients with CEBPA high-meth than those in CEBPA low-meth . On the other hand, CEBPA methylation did not correlate with gender, white blood cell count, hemoglobin level, platelet count or lactate dehydrogenase level.
Several reports including ours have shown that NPM1 mutation is mutually exclusive with CEBPA mutation in AML. 30, 32 To determine the correlation of CEBPA methylation with mutations in CEBPA, NPM1 and other genetic alterations frequently reported in AML, including FLT3, PTPN11, JAK2, N-RAS, K-RAS, MLL, KIT, RUNX1 and WT1, we analyzed these genes in patients with high and low CEBPA methylation levels. As expected, NPM1 mutation was mutually exclusive with CEBPA methylation (P ¼ 0.004). Of the 28 patients with high CEBPA methylation, only one patient harbored CEBPA mutation, whereas other genetic alterations were not in parallel with the CEBPA methylation ( Table 2) .
Previous immunophenotyping studies revealed that the CEBPA mutation was associated with HLA-
þ cells in AML. 9 Furthermore, compared to those with CEBPA single-mut , patients harboring CEBPA double-mut had higher expression levels of HLA-DR, CD7 and CD15 coupled with a lower CD56 on the harvested leukemia cells. 16 By contrast, leukemic blasts isolated from CEBPA high-meth were predominately negative for the expression of HLA-DR (46.4%, P ¼ 0.005) and CD56 (3.7%, P ¼ 0.015; Table 3 ).
Impact of CEBPA methylation in response to therapy and clinical outcome
Of the 125 patients receiving standard induction therapy, 95 (76.0%) patients achieved a CR. CEBPA high-meth was associated with a trend toward favorable treatment response (CR rate 93.3% versus 73.6%, P ¼ 0.116) than those with CEBPA low-meth . With a median follow-up of 48 months, CEBPA high-meth was associated with a better OS than CEBPA low-meth after excluding patients with favorable karyotypes, NPM1 mutation (NPM1 mt ) and CEBPA mutations (CEBPA mt ) (34 versus 12 months, P ¼ 0.031; Figure 3a) . Subgroup analysis further showed that the OS of patients with CEBPA high-meth (n ¼ 7) was longer than those of CEBPA low-meth in patients with normal karyotypes, but without CEBPA and NPM1 mutations (n ¼ 18; median 460 versus 12 months, P ¼ 0.028; Figure 3b ). Limited by small number of patients, the patients with CEBPA high-meth (n ¼ 5) did not show survival advantage over those of CEBPA low-meth (n ¼ 22; P ¼ 0.247; Figure 3c ) in patients with normal karyotype and negative of NPM1 mutation and FLT3-ITD. Similarly, no survival advantage was shown in patients with normal karyotype and negative of NPM1 mutation, CEBPA mutation and FLT3-ITD (P ¼ 0.140; Figure 3d ), and no survival difference shown between patients with CEBPA high-meth (n ¼ 7) and with CEBPA low-meth (n ¼ 15; P ¼ 0.211 for OS and P ¼ 0.108 for disease-free survival (DFS)) in a subgroup with positive FLT3-ITD and negative NPM1 mutation. By including NPM1, FLT3/ITD, CEBPA, karyotype and age as covariates in the multivariate analysis, we concluded that increased CEBPA methylation was an independent favorable prognostic factor Table 4 ). These results suggest that CEBPA methylation status could emerge as a prognostic biomarker for survival advantage, in addition to current cytogenetic and molecular markers in AML patients.
Discussion
A cohort of 193 patients with de novo AML were enrolled in the CEBPA methylation study presented herein. Overall, patients with CEBPA high-meth had better response to standard induction therapy than those with CEBPA high-meth (CR rate 93.3 versus 73.6%). For studies in the patients with normal karyotype, patients with CEBPA high-meth had better survival rates than those with CEBPA low-meth in the subgroup with negative of CEBPAmt and NPM1mt (P ¼ 0.028). Furthermore, the multivariate analysis showed that high CEBPA methylation was an independent prognostic biomarker for improved DFS. To the best of our knowledge, this is the first report on the clinical implications of CEBPA promoter hypermethylation in unselected patients with de novo AML.
Hypermethylation of the CEBPA core promoter region is rarely found in patients with AML. 24, 25 In our study, only one female patient with M1 showed extensive CEBPA methylation at the core promoter region as well as the proximal and distal promoter regions. Leukemia cells from this patient expressed CD7 and carried a NOTCH1 mutation (data not shown), findings similar to a subgroup of AML with CEBPA sil (silenced CEBPA coupled with NOTCH1 mutation) categorized by Wouters et al. 25 On the other hand, hypermethylation of CEBPA distal promoter has been frequently found in lung cancer, head and neck squamous cell carcinoma and AML. [5] [6] [7] In this study, we performed comprehensive methylation analyses of the CpG islands located at the CEBPA promoter, and concluded that methylation in the distal, but not proximal or core promoter region, was detected in a substantial proportion of AML patients. Although most epigenetic dysregulation in cancer are believed to be localized at the core promoter of tumor suppressor genes, hypermethylation of the distal CEBPA promoter region could disrupt the binding of upstream stimulatory factor, which is essential for proper CEBPA expression, 5 resulting in the downregulation of CEBPA expression. Furthermore, for those patients with hypermethylation in the distal CEBPA promoter region, only three patients had CD7 þ leukemic cells, and one carried additional NOTCH1 mutation (data not shown), showing that patients with increased methylation at the distal CEBPA promoter region had different clinical features from the CEBPA sil subgroup.
We used MassARRAY quantitative methylation coupled with linkage clustering to categorize the patients with de novo AML into CEBPA high-meth and CEBPA low-meth groups and explored the potential clinical impact, by hypermethylation, on CEBPA distal promoter in these patients. A cutoff methylation level of 0.543, corresponding to an area under the receiver operating characteristic curve value of 1.000 (95% confidence interval, 0.981-1.000, Po0.0001), was installed for both sensitivity and specificity of 100.00% to differentiate CEBPA high-meth and CEBPA low-meth groups (Supplementary Figure S3) . We intend to continue to enroll patients with de novo AML patient to further validate the distinct clinical outcome associated with CEBPA high-meth or CEBPA low-meth group using current cutoff methylation level. However, the cutoff methylation level should be fine-tuned in each laboratory before use. In contrast to the current concept that genomic DNA becomes hypermethylated with age, we found that higher CEBPA methylation occurred more frequently in younger patients. This scenario pointed to the critical importance of CEBPA methylation. Several reports including ours have shown that NPM1 mutation is mutually exclusive with CEBPA mutation Figure 3 Kaplan-Meier survival analysis according to the CEBPA methylation status. The CEBPA high-meth showed a longer OS than the CEBPA low-meth after excluding patients with favorable karyotypes (inv(16), t(15;17) and t(8;21)), CEBPA mutation and NPM1 mutations (a). Among the patients with normal karyotype, CEBPA high-meth showed a significantly longer OS than CEBPA low-meth in a subgroup with negative CEBPA and NPM1 mutations (b). OS analysis of CEBPA high-meth and CEBPA low-meth in subgroup with normal karyotype and negative of NPM1 mutation and FLT3-ITD (c), and in a subgroup with normal karyotype and negative of CEBPA and NPM1 mutations and FLT3-ITD (d). CEBPA methylation as a biomarker in AML patients T-C Lin et al in AML, and both CEBPA mutation and NPM1 mutation were common genetic alterations for favorable prognosis in AML. 30, 32 Our present study showed that CEBPA hypermethylation was mutually exclusive with NPM1 mutation (P ¼ 0.004), and only one patient had additional CEBPA mutation in the CEBPA high-meth group. Simultaneously, we showed that the AML patients with high CEBPA methylation have survival advantage upon receiving standard treatment, similar to the patients with CEBPA mutation or NPM1 mutation. This implicates that nucleophosmin and C/EPBa play important and related roles in myeloid differentiation, and dysregulation will promote myeloid leukemogenesis. Recently, Mü ller et al. 33 discovered that the interaction of nucleophosmin and extended-C/EBPa (a novel translational isoform of C/EPBa translated from an alternative non-AUG initiation codon), together with the Pol I-specific factors upstream-binding factor 1 and SL1, could stimulate rRNA synthesis, which was required for cell growth and proliferation of leukemia cells.
Given that the hypermethylation of CEBPA distal promoter was associated with higher CR rate and lower probability of primary refractory status, CEBPA hypermethylation might be used as a biomarker to predict clinical outcomes following validation in independent data sets. In addition, we showed a positive correlation between low CEBPA methylation and HLA-DR and CD56 expression in leukemic cells. Previous reports have shown that the expression of CD56 and HLA-DR þ / CD34 þ is associated with shorter CR duration and worse clinical prognosis. [34] [35] [36] [37] This is consistent with the inferior survival in patients with CEBPA low-meth . APL is characterized by t(15;17)(q22;q12) chromosomal translocation, creating a PML/RARA fusion gene. Previous reports have shown that PML/RARa recruits HDAC, DNMT and MBD to epigenetically suppress CEBPA expression and block the granulocytic differentiation. [38] [39] [40] Treatment with retinoic acid or overexpression of C/EBPa accelerated the granulocytic maturation of APL cells. 41, 42 It is possible that CEBPA reactivation is required for retinoic acid-induced differentiation of APL cells. It is worth noting that 75% of the AML patients with t(15;17) translocation had CEBPA hypermethylation. Thus, CEBPA suppression caused by hypermethylation of the CEBPA distal promoter may be one of the epigenetic changes arising from PML/RARa in APL.
Figueroa et al. 43 recently reported that patients with CEBPA sil (n ¼ 4) had considerably worse disease outcomes than those with CEBPA mutation (CEBPA mut , n ¼ 4). One patient with CEBPA sil was found in this study, and she had an OS of 10 months, with a DFS of 8 months. In addition, our recent findings indicated that the patients with CEBPA double mutation (CEBPA double-mut ) had a significant longer OS and DFS than those with wild-type CEBPA (CEBPA wild ) or CEBPA single mutation (CEBPA single-mut ) among the subgroup of patients with normal karyotype. 16 In this cohort study, we did not see any survival difference between CEBPA high-meth (n ¼ 25) and those with CEBPA mut (n ¼ 17; OS, P ¼ 0.410; DFS, P ¼ 0.327), except one patient with both CEBPA mutation and high CEBPA methylation. Similar results were noted in comparison with CEBPA high-meth (n ¼ 25) and CEBPA double-mut (n ¼ 13; OS, P ¼ 0.461; DFS, P ¼ 0.418).
In conclusion, this study shows that hypermethylation on the distal CEBPA promoter was detected in a substantial proportion of patients with de novo AML and was closely associated with decreased CEBPA expression, younger age, French-AmericanBritish subtypes and favorable karyotypes. We only detected additional mutations of the CEBPA genes in one out of 28 patients with CEBPA high-meth . Furthermore, the CEBPA hypermethylation was an independent prognostic marker for longer DFS and OS periods, especially in the subgroup excluding patients with favorable cytogenetic/molecular markers. Taken together, our results unequivocally supported that hypermethylation of the CEBPA distal promoter could be beneficial for the clinical outcome of patients with de novo AML.
